News
Category: CHDI
Huntington’s Disease consortium further validates IXICO’s AI imaging platform
12 February 2025 - London, UK. IXICO plc (AIM: IXI, “IXICO” or “the Company”) a global leader in neuroscience imaging, using its AI-driven platform to help advance drug development in neurological disorders, today announces, the generation of further evidence verifying the superiority of the ‘IXIQ.Ai’ analysis platform in the development and validation of imaging biomarkers for Huntington’s Disease (HD), in conjunction with the Huntington’s Disease Imaging Harmonisation (“HD-IH”) consortium.
Huntington’s Disease Image Harmonization Consortium secures new member and funding to complete large-scale analysis of brain changes using IXIQ.Ai
New York, NY / London, UK, July, 12th 2023; The Huntington’s Disease Imaging Harmonization (HD-IH) Consortium, founded last year to conduct an unprecedented harmonization analysis of more than 6,000 participant-visit magnetic resonance images (MRIs) acquired from over 2,000 research participants, has now completed the initial phase and secured the necessary funding commitment to complete the…
Call to Action – New consortium will use artificial intelligence technology to conduct large-scale analysis of brain changes in Huntington’s disease
Published on: September 21, 2022 View the full News here; Call to Action – New consortium will use artificial intelligence technology to conduct large-scale analysis of brain changes in Huntington’s disease About IXICO | Advanced Analytics | Intelligent Insights.